Citigroup Issues Positive Forecast for 10x Genomics (NASDAQ:TXG) Stock Price

10x Genomics (NASDAQ:TXG) had its price target increased by investment analysts at Citigroup from $50.00 to $60.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Citigroup‘s target price indicates a potential upside of 1.21% from the company’s previous close.

TXG has been the topic of a number of other reports. Leerink Partners increased their price objective on shares of 10x Genomics from $40.00 to $90.00 and gave the company a “market perform” rating in a research report on Tuesday, September 29th. UBS Group reaffirmed a “neutral” rating and set a $61.00 price objective on shares of 10x Genomics in a research report on Friday. Stifel Nicolaus increased their target price on 10x Genomics from $50.00 to $68.00 and gave the company a “buy” rating in a report on Friday. Canaccord Genuity Group increased their target price on 10x Genomics from $60.00 to $100.00 and gave the company a “buy” rating in a report on Monday, October 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 10x Genomics in a research note on Monday, September 21st. Five analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $68.07.

10x Genomics Stock Performance

Shares of TXG traded up $1.22 during midday trading on Friday, hitting $59.28. The company had a trading volume of 4,521,141 shares, compared to its average volume of 3,031,030. The company’s 50-day simple moving average is $74.06 and its 200-day simple moving average is $41.41. The firm has a market capitalization of $7.72 billion, a P/E ratio of -100.47 and a beta of 2.03. 10x Genomics has a 1 year low of $13.58 and a 1 year high of $102.81.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The firm had revenue of $150.67 million for the quarter, compared to analysts’ expectations of $147.96 million. During the same quarter last year, the company earned ($0.22) earnings per share. The firm’s revenue was up 1.1% compared to the same quarter last year. Equities analysts predict that 10x Genomics will post -0.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Adam Taich sold 46,388 shares of 10x Genomics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total transaction of $2,995,273.16. Following the sale, the chief financial officer owned 316,344 shares in the company, valued at approximately $20,426,332.08. The trade was a 12.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John R. Stuelpnagel sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total value of $1,235,000.00. Following the completion of the sale, the director owned 328,436 shares of the company’s stock, valued at approximately $20,280,923. This represents a 5.74% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 179,333 shares of company stock worth $11,810,070. 8.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On 10x Genomics

Several hedge funds have recently made changes to their positions in the business. Quantinno Capital Management LP grew its stake in shares of 10x Genomics by 16.0% in the 1st quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after purchasing an additional 744,558 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of 10x Genomics by 34.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock worth $43,357,000 after purchasing an additional 525,369 shares during the last quarter. Counterpoint Mutual Funds LLC purchased a new stake in shares of 10x Genomics during the third quarter worth approximately $11,364,000. Quantedge Capital Pte Ltd lifted its holdings in shares of 10x Genomics by 104.2% during the first quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock worth $8,843,000 after purchasing an additional 212,600 shares during the period. Finally, Fulcrum Asset Management LLP acquired a new stake in shares of 10x Genomics during the third quarter worth $8,793,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ estimate of $0.27, while revenue of $150.7 million topped expectations of $148.0 million. 10x Genomics Q3 results
• Positive Sentiment: The company raised its 2026 revenue forecast to $625 million–$635 million, above the roughly $620 million consensus. Management cited Atera demand and spatial consumables growth, and targets about 50 Atera shipments by year-end. Q3 earnings call highlights
• Positive Sentiment: 10x launched Sentira Single Cell, a Claude-powered AI tool designed to simplify cell-data analysis. The product could make research workflows easier and create recurring revenue opportunities. Sentira AI tool launch
• Neutral Sentiment: Citi raised its price target to $60 but maintained a Neutral rating, suggesting a somewhat improved view without a shift to a bullish recommendation. Citi price-target update
• Negative Sentiment: Management flagged production constraints and margin pressure as ongoing challenges, which could limit the benefits of stronger demand and growth. Q3 earnings call highlights
• Negative Sentiment: UBS cut its price target to $61 from $90 and kept a Neutral rating, signaling reduced expectations despite the raised company outlook. UBS price-target update

About 10x Genomics

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.